SynthesisBMC gastroenterology2025
Global prevalence of chronic kidney disease and its influencing factors among chronic hepatitis B: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence and predictive factors of chronic kidney disease among individuals with cardiometabolic risk factors: A multicenter cross-sectional study, North East Ethiopia.Clinical medicine (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundA comprehensive understanding of the prevalence of chronic kidney disease (CKD) among patients with chronic hepatitis B (CHB) is lacking. To fill this knowledge gap, we conducted a systematic review and meta-analysis to assess the prevalence of CKD and its associated factors among CHB patients.
methodsFollowing the PRISMA guidelines, we conducted a comprehensive search for literature published between January 1, 2010, and January 5, 2025, in databases including PubMed, Embase, Cochrane Library, Web of Science, CNKI, and Wanfang. The prevalence of CKD among CHB individuals was used as the statistical effect size, and the 95% confidence interval (CI) was calculated. Additionally, we compared the risk of CKD between CHB and non-HBV-infected populations, expressed as odds ratios (OR). Furthermore, subgroup analyses were performed based on factors such as year of publication, study sample size, age, CKD diagnostic basis, country, WHO region, economic status, presence of cirrhosis, diabetes, and antiviral treatment status to further explore the influencing factors of CKD among CHB individuals. Subgroup results were corrected using Holm–Bonferroni correction, and meta-regression was used to explore sources of heterogeneity.
resultsA total of 41 studies were included in our analysis, of which 30 were deemed high-quality. These studies collectively encompassed 1,066,919 CHB patients, among whom 44,021 were diagnosed with CKD. The meta-analysis demonstrated a significantly elevated CKD risk in CHB populations versus non-hepatitis B controls (OR = 2.30, 95%CI: 2.01–2.63). Due to substantial between-study heterogeneity, we performed subgroup analyses which revealed: the highest prevalence in studies published during 2021–2024 (11.48%, 95%CI: 6.08%-21.61%); numerically but non-significantly higher prevalence in patients aged ≥ 50 years (21.87%, 95%CI:0.41%-64.78%) versus younger patients (4.68%, 95%CI: 0.50%-32.57%, p > 0.05) and in diabetic (17.78%, 95%CI: 1.91%-70.58%) versus non-diabetic patients (1.52%, 95%CI: 0.61%-3.69%, p > 0.05). CKD prevalence was significantly higher when diagnosed by persistent eGFR < 60 mL/min/1.73 m² (12.20%, 95%CI: 6.04%-23.09%) versus other criteria. Antiviral-treated patients showed higher prevalence (11.37%, 95%CI:8.62%-14.86%) than untreated counterparts (4.09%, 95%CI:2.63%-6.31%). Meta-regression identified age, diabetes status and antiviral treatment as heterogeneity sources.
conclusionsThis study reveals a higher prevalence of CKD in patients with CHB. Subgroup analysis indicated that groups with cirrhosis, diabetes, and a history of antiviral therapy exhibited even higher prevalence rates. These findings suggest that individualized management strategies tailored to specific subgroups of CHB patients may enhance the prevention and management of comorbid conditions. However, due to age, region, and other natural differences in populations, the observed prevalence shows great heterogeneity. Therefore, the results should be interpreted with caution given the high degree of heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.